

Jonathan A Ledermann

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8999932/jonathan-a-ledermann-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88

papers

12,012

citations

35

h-index

94

g-index

94

ext. papers

15,099

ext. citations

9.1

avg, IF

6.01

L-index

#	Paper	IF	Citations
88	The path for medical associations to sponsor trustworthy guidelines: is it feasible?. <i>Journal of the Royal Society of Medicine</i> , 2022 , 1410768221095240	2.3	0
87	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 12-39	3.5	203
86	British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic. <i>International Journal of Gynecological Cancer</i> , 2021 ,	3.5	2
85	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , 2021 ,	13.4	6
84	Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. <i>British Journal of Cancer</i> , 2021 , 125, 1666-1676	8.7	2
83	Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. <i>Cancer</i> , 2021 , 127, 2432-2441	6.4	6
82	Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. <i>ESMO Open</i> , 2021 , 6, 100043	6	6
81	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 620-631	21.7	58
80	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 949-958	3.5	0
79	Frontline Maintenance Treatment for Ovarian Cancer. <i>Current Oncology Reports</i> , 2021 , 23, 97	6.3	1
78	ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1014-1023	3.5	8
77	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. <i>Cancer Medicine</i> , 2021 , 10, 7162-7173	4.8	2
76	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , 2021 , 154, 190-200	7.5	1
75	Immune checkpoint inhibitors in ovarian cancer: where do we stand?. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211039899	5.4	4
74	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2020 , 21, 969-977	21.7	13
73	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 710-722	21.7	28
72	British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU). <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 695-700	3.5	21

71	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 6002-6002	2.2	54
70	Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 221-226	3.5	7
69	A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2020 , 159, 692-698	4.9	8
68	ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies. <i>ESMO Open</i> , 2020 , 5,	6	8
67	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3494-3505	2.2	13
66	Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CANcer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?. <i>Current Opinion in Oncology</i> , 2020 , 32, 442-450	4.2	4
65	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020 , 159, 101-111	4.9	7
64	Olaparib maintenance for first-line treatment of ovarian cancer: Will SOLO1 reset the standard of care?. <i>Future Oncology</i> , 2019 , 15, 1845-1853	3.6	10
63	Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3183-3191	2.2	15
62	Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919849753	5.4	49
61	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2257-2269	2.2	69
60	Extending the scope of PARP inhibitors in ovarian cancer. <i>Lancet Oncology, The</i> , 2019 , 20, 470-472	21.7	7
59	Combining conventional therapy with immunotherapy: A risky business?. <i>European Journal of Cancer</i> , 2019 , 113, 41-44	7.5	11
58	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1273-1285	21.7	160
57	Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application. <i>Clinical Trials</i> , 2019 , 16, 502-511	2.2	6
56	JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9-TPS9	2.2	10
55	Maintenance Treatment for Recurrent Ovarian Carcinoma Evidence Supporting the Efficacy and Safety of PARP Inhibitors. <i>European Oncology and Haematology</i> , 2019 , 15, 29	0.1	0
54	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. <i>Lancet, The</i> , 2019 , 394, 2084-2095	40	88

53	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2019 , 152, 53-60	4.9	26
52	Mainstreamed genetic testing for women with ovarian cancer: first-year experience. <i>Journal of Medical Genetics</i> , 2019 , 56, 195-198	5.8	28
51	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 295-309	21.7	263
50	Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5537-5537	2.2	2
49	Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. <i>British Journal of Cancer</i> , 2018 , 119, 1075-1085	8.7	86
48	Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. <i>British Journal of Cancer</i> , 2018 , 119, 1401-1409	8.7	100
47	Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. <i>Clinical Cancer Research</i> , 2017 , 23, 4086-4094	12.9	83
46	Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial. <i>Cancer</i> , 2017 , 123, 2752-2761	6.4	20
45	The European Society for Medical Oncology (ESMO) Congress 2016: Highlights and summary of selected abstracts in gynecologic cancers. <i>Gynecologic Oncology</i> , 2017 , 144, 8-10	4.9	
44	Targeted Therapies for Ovarian Cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017 , 41, 139-152	4.6	53
43	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 1949-1961	4.0	815
42	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1274-1284	21.7	913
41	Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review. <i>Gynecologic Oncology</i> , 2017 , 144, 57-60	4.9	8
40	High-Grade Carcinomas, BRCA Mutations and the Role of PARP Inhibitors 2017 , 171-182		
39	Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5533-5533 ¹⁹		
38	Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. <i>Oncotarget</i> , 2017 , 8, 43653-43661	3.3	67
37	Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1579-1589	21.7	296
36	Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. <i>British Journal of Cancer</i> , 2016 , 115, 1313-1320	8.7	47

35	Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. <i>Cancer</i> , 2016 , 122, 1844-52	6.4	62
34	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 2-30	3.5	358
33	Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease. <i>Gynecologic Oncology Reports</i> , 2016 , 18, 22-24	1.3	21
32	Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 1066-1074	4.0	170
31	Homologous recombination deficiency and ovarian cancer. <i>European Journal of Cancer</i> , 2016 , 60, 49-58	7.5	116
30	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 2154-2164	59.2	1259
29	The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib. <i>Clinical Advances in Hematology and Oncology</i> , 2016 , 14, 619-27	0.6	8
28	The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations. <i>Clinical Advances in Hematology and Oncology</i> , 2016 , 14, 704-11	0.6	4
27	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology, The</i> , 2015 , 16, 928-36	21.7	475
26	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Modern Pathology</i> , 2015 , 28, 1101-22	9.8	107
25	An overview of early investigational therapies for chemoresistant ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1163-83	5.9	12
24	Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials. <i>Cancer</i> , 2015 , 121, 1737-46	6.4	45
23	ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2015 , 117, 559-81	5.3	131
22	PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions. <i>British Journal of Cancer</i> , 2015 , 113 Suppl 1, S10-6	8.7	22
21	Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in BRCA1 or BRCA2 are biologically similar and sensitive to PARP inhibition 2015 ,		2
20	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 852-61	21.7	1007
19	Ovarian cancer. <i>Lancet, The</i> , 2014 , 384, 1376-88	4.0	1123
18	Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2014 , 6, 229-39	5.4	150

17	Gynecologic Cancer InterGroup (GCIg) consensus review for mucinous ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, S14-9	3.5	64
16	Maintenance therapy in ovarian cancer. <i>Current Opinion in Oncology</i> , 2014 , 26, 521-8	4.2	20
15	Novel approaches to improve the treatment of rare gynecologic cancers: research opportunities and challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e282-6	7.1	5
14	Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. <i>Clinical Cancer Research</i> , 2013 , 19, 5227-39	12.9	54
13	Tumor-related and treatment-related colostomy-free survival (CFS) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU/CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA): Results of ACT II.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3532-3532	2.2	
12	Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 1382-92	59.2	1265
11	Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery. <i>International Journal of Gynecological Cancer</i> , 2012 , 22, 566-72	3.5	11
10	A phase 3 trial of bevacizumab in ovarian cancer. <i>New England Journal of Medicine</i> , 2011 , 365, 2484-96	59.2	1454
9	Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3798-804	2.2	182
8	Cryptogenic colitis due to occult cytomegalovirus infection. <i>Frontline Gastroenterology</i> , 2011 , 2, 57-62	2.6	
7	Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4187-93	2.2	61
6	How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?. <i>Cancer Investigation</i> , 2004 , 22 Suppl 2, 2-10	2.1	5
5	High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). <i>Annals of Oncology</i> , 2001 , 12, 693-9	10.3	29
4	High dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2000 , 10, 53-56	3.5	9
3	Tumor Markers in Ovarian Malignancies. <i>Oncologist</i> , 1997 , 2, 324-329	5.7	27
2	Tumor Markers in Ovarian Malignancies. <i>Oncologist</i> , 1997 , 2, 324-329	5.7	13
1	Topography of NCAM antigenic epitopes recognized by SCLC-cluster-1 antibodies. A consensus view. <i>International Journal of Cancer</i> , 1994 , 8, 27-9	7.5	10